Bbva Compass Bancshares Inc. cut its position in Allergan PLC (NYSE:AGN) by 38.2% during the second quarter, Holdings Channel reports. The fund owned 11,466 shares of the company’s stock after selling 7,100 shares during the period. Bbva Compass Bancshares Inc.’s holdings in Allergan PLC were worth $2,649,000 at the end of the most recent reporting period.
Several other hedge funds have also added to or reduced their stakes in the company. Johnston Asset Management LLC acquired a new stake in Allergan PLC during the second quarter worth $134,170,000. Adage Capital Partners GP L.L.C. raised its stake in Allergan PLC by 78.5% in the first quarter. Adage Capital Partners GP L.L.C. now owns 1,245,934 shares of the company’s stock worth $333,948,000 after buying an additional 547,759 shares during the last quarter. First Manhattan Co. raised its stake in Allergan PLC by 117.2% in the second quarter. First Manhattan Co. now owns 694,036 shares of the company’s stock worth $160,384,000 after buying an additional 374,443 shares during the last quarter. 1832 Asset Management L.P. raised its stake in Allergan PLC by 92.4% in the first quarter. 1832 Asset Management L.P. now owns 670,565 shares of the company’s stock worth $310,259,000 after buying an additional 322,020 shares during the last quarter. Finally, American Century Companies Inc. raised its stake in Allergan PLC by 32.2% in the second quarter. American Century Companies Inc. now owns 1,212,392 shares of the company’s stock worth $280,172,000 after buying an additional 295,479 shares during the last quarter. Hedge funds and other institutional investors own 85.19% of the company’s stock.
Shares of Allergan PLC (NYSE:AGN) traded down 1.79% during midday trading on Friday, hitting $228.20. 2,211,676 shares of the company’s stock were exchanged. The firm has a market cap of $90.36 billion, a PE ratio of 21.73 and a beta of 0.81. Allergan PLC has a one year low of $195.50 and a one year high of $322.68. The stock’s 50-day moving average price is $238.26 and its 200 day moving average price is $238.38.
Allergan PLC (NYSE:AGN) last issued its quarterly earnings data on Monday, August 8th. The company reported $3.35 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.34 by $0.01. Allergan PLC had a return on equity of 7.67% and a net margin of 28.06%. The company had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $4.10 billion. During the same quarter last year, the business posted $4.41 earnings per share. The firm’s revenue was up 1.0% compared to the same quarter last year. Equities research analysts forecast that Allergan PLC will post $14.00 EPS for the current year.
AGN has been the topic of a number of research reports. Goldman Sachs Group Inc. reiterated a “buy” rating on shares of Allergan PLC in a research note on Wednesday, July 6th. Leerink Swann raised their price target on shares of Allergan PLC from $272.00 to $294.00 and gave the company an “outperform” rating in a research report on Wednesday, July 27th. JPMorgan Chase & Co. set a $325.00 price target on shares of Allergan PLC and gave the company a “buy” rating in a research report on Friday, August 5th. Zacks Investment Research lowered shares of Allergan PLC from a “buy” rating to a “hold” rating in a research report on Tuesday, July 26th. Finally, Vetr upgraded shares of Allergan PLC from a “buy” rating to a “strong-buy” rating and set a $285.60 price target on the stock in a research report on Monday, August 1st. Six equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. Allergan PLC has an average rating of “Buy” and an average price target of $302.23.
Allergan PLC Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.